patent term extension case law in japan
DESCRIPTION
AIPLA 2009 Annual Meeting IP Practice in Japan Committee - Premeeting October 13-14, 2009TRANSCRIPT
LAW
DIVIS
ION
PATENT
DIVIS
ION
TRADEMARK
& DESIG
N
DIVIS
ION
ACCOUNTING
& AUDIT
ING
DIVIS
ION
YUASA AND HARALAW, PATENT, TRADEMARK & DESIGN and ACCOUNTING
YUASA AND HARALAW, PATENT, TRADEMARK & DESIGN and ACCOUNTING
1
LAW
DIVIS
ION
PATENT
DIVIS
ION
TRADEMARK
& DESIG
N
DIVIS
ION
ACCOUNTING
& AUDIT
ING
DIVIS
ION
YUASA AND HARALAW, PATENT, TRADEMARK & DESIGN and ACCOUNTING
LAW
DIVIS
ION
PATENT
DIVIS
ION
TRADEMARK
& DESIG
N
DIVIS
ION
ACCOUNTING
& AUDIT
ING
DIVIS
ION
YUASA AND HARALAW, PATENT, TRADEMARK & DESIGN and ACCOUNTING
AIPLA 2009 Annual MeetingIP Practice in Japan Committee - Pre-meeting
October 14, 2009
Koji Hirayama YUASA and HARA
Patent Term Extension:Case Law in Japan
LAW
DIVIS
ION
PATENT
DIVIS
ION
TRADEMARK
& DESIG
N
DIVIS
ION
ACCOUNTING
& AUDIT
ING
DIVIS
ION
YUASA AND HARALAW, PATENT, TRADEMARK & DESIGN and ACCOUNTING
YUASA AND HARALAW, PATENT, TRADEMARK & DESIGN and ACCOUNTING
2
Life Cycle Management of Drugs
Introductory Period Growth Period Maturation Period Declining Period
Perform sales promotion activity
Sales decrease due to a drop in market share and price
Sales startHit the marketSales expand
Acquire profits to recoup research and development costs
time
sales
Profitability point
Patent TermEntry of Generic Drugs
Sales Authorization by Government
LAW
DIVIS
ION
PATENT
DIVIS
ION
TRADEMARK
& DESIG
N
DIVIS
ION
ACCOUNTING
& AUDIT
ING
DIVIS
ION
YUASA AND HARALAW, PATENT, TRADEMARK & DESIGN and ACCOUNTING
YUASA AND HARALAW, PATENT, TRADEMARK & DESIGN and ACCOUNTING
3
Life Cycle Management of Drugs (cont’d)
Introductory Period Growth Period Maturation Period Declining Period
“Gross Sales”Authorization by Government
Entry of Generic Drugs
• How to Maximize “Gross Sales” ?
• Accelerate the start of sales by expediting authorization from government
• Delay the entry of generic drugs by “patent term extension”
“Gross Sales”Patent Term Extension
Expediting authorization
LAW
DIVIS
ION
PATENT
DIVIS
ION
TRADEMARK
& DESIG
N
DIVIS
ION
ACCOUNTING
& AUDIT
ING
DIVIS
ION
YUASA AND HARALAW, PATENT, TRADEMARK & DESIGN and ACCOUNTING
YUASA AND HARALAW, PATENT, TRADEMARK & DESIGN and ACCOUNTING
4
Concept of Patent Term Extension
• If the patented invention could not be worked for the necessity of obtaining a marketing approval provided under legal regulations designed for ensuring product safety
Ex. Drug, Pesticide (Japan)
• Benefit of exclusive rights cannot be enjoyed despite the validity of patent rights.
• Such situations pose problems affecting the basis of the patent system, and a measure of extending the patent terms is necessary in order to resolve the situation.
LAW
DIVIS
ION
PATENT
DIVIS
ION
TRADEMARK
& DESIG
N
DIVIS
ION
ACCOUNTING
& AUDIT
ING
DIVIS
ION
YUASA AND HARALAW, PATENT, TRADEMARK & DESIGN and ACCOUNTING
YUASA AND HARALAW, PATENT, TRADEMARK & DESIGN and ACCOUNTING
5
Patent Term Extension System
registrationdate
filing date clinicaltrial
startingdate
approval by government
20 yearsfrom
filing date
whicheveris later
extensionperiod
0 < extension period 5 years≦
extensionperiod
Patent Term
working of the patent right prohibited
LAW
DIVIS
ION
PATENT
DIVIS
ION
TRADEMARK
& DESIG
N
DIVIS
ION
ACCOUNTING
& AUDIT
ING
DIVIS
ION
YUASA AND HARALAW, PATENT, TRADEMARK & DESIGN and ACCOUNTING
YUASA AND HARALAW, PATENT, TRADEMARK & DESIGN and ACCOUNTING
6
US *1 JP *2
Products applicable for patent term extension
drugs, medical equipment,food additives, artificial
colorsdrugs, pesticides
Term to be extendedup to 5 yrs
(within 14 yrs from approval)up to 5 yrs
Patent(s) extendible based on one approval
only one patentchosen by applicant
one or more patents relating to approved
product
Number of times for one patent to be extended
only once no limitation
Effect of extended patent right
Limited to approved product, but including a later-approved
use
Limited to approved product and use
*1 35 USC §§155-156 *2 Japanese patent law §67bis
Brief Comparison – US v. JP
LAW
DIVIS
ION
PATENT
DIVIS
ION
TRADEMARK
& DESIG
N
DIVIS
ION
ACCOUNTING
& AUDIT
ING
DIVIS
ION
YUASA AND HARALAW, PATENT, TRADEMARK & DESIGN and ACCOUNTING
YUASA AND HARALAW, PATENT, TRADEMARK & DESIGN and ACCOUNTING
7
“Multiple patents” corresponding to one approval
chemical substance patent
medical use A patent
production process patent
filingdate
filingdate
filingdate
time
patent term expires
patent term expires
patent term expires
extension period
extension period
extension period
All the patents individually extendible as long as there is a necessity to obtain an approval for the working of each of the patented inventions
LAW
DIVIS
ION
PATENT
DIVIS
ION
TRADEMARK
& DESIG
N
DIVIS
ION
ACCOUNTING
& AUDIT
ING
DIVIS
ION
YUASA AND HARALAW, PATENT, TRADEMARK & DESIGN and ACCOUNTING
YUASA AND HARALAW, PATENT, TRADEMARK & DESIGN and ACCOUNTING
88
US *1 JP *2
Products applicable for patent term extension
drugs, medical equipment,food additives, artificial
colorsdrugs, pesticides
Term to be extendedup to 5 yrs
(within 14 yrs from approval)up to 5 yrs
Patent(s) extendible based on one approval
only one patentchosen by applicant
one or more patents relating to approved
product
Number of times for one patent to be extended
only once no limitation
Effect of extended patent right
Limited to approved product, but including a later-approved
use
Limited to approved product and use
*1 35 USC §§155-156 *2 Japanese patent law §67bis
Brief Comparison – US v. JP
LAW
DIVIS
ION
PATENT
DIVIS
ION
TRADEMARK
& DESIG
N
DIVIS
ION
ACCOUNTING
& AUDIT
ING
DIVIS
ION
YUASA AND HARALAW, PATENT, TRADEMARK & DESIGN and ACCOUNTING
YUASA AND HARALAW, PATENT, TRADEMARK & DESIGN and ACCOUNTING
9
“Multiple approvals” corresponding to one patent
Chemical substance patent
patent term expires
filingdate
extension periodfor medical use A
extension period for medical use B
extension period5 years maximum
time
patent term20 years
Extension may be granted for each of the different medical uses
LAW
DIVIS
ION
PATENT
DIVIS
ION
TRADEMARK
& DESIG
N
DIVIS
ION
ACCOUNTING
& AUDIT
ING
DIVIS
ION
YUASA AND HARALAW, PATENT, TRADEMARK & DESIGN and ACCOUNTING
YUASA AND HARALAW, PATENT, TRADEMARK & DESIGN and ACCOUNTING
1010
US *1 JP *2
Products applicable for patent term extension
drugs, medical equipment,food additives, artificial
colorsdrugs, pesticides
Term to be extendedup to 5 yrs
(within 14 yrs from approval)up to 5 yrs
Patent(s) extendible based on one approval
only one patentchosen by applicant
one or more patents relating to approved
product
Number of times for one patent to be extended
only once no limitation
Effect of extended patent right
Limited to approved product, but including a later-approved
use
Limited to approved product and use
*1 35 USC §§155-156 *2 Japanese patent law §67bis
Brief Comparison – US v. JP
LAW
DIVIS
ION
PATENT
DIVIS
ION
TRADEMARK
& DESIG
N
DIVIS
ION
ACCOUNTING
& AUDIT
ING
DIVIS
ION
YUASA AND HARALAW, PATENT, TRADEMARK & DESIGN and ACCOUNTING
YUASA AND HARALAW, PATENT, TRADEMARK & DESIGN and ACCOUNTING
11
Statutory Requirements
• [T]here is a period during which the patented invention is unable to be worked because […] “[a] disposition designated by Cabinet Order” […] is necessary to obtain for the working of the patented invention… Section 67(2)• Marketing approval for drugs and pesticides
• What acts are covered by “the working of the patented invention” ?
LAW
DIVIS
ION
PATENT
DIVIS
ION
TRADEMARK
& DESIG
N
DIVIS
ION
ACCOUNTING
& AUDIT
ING
DIVIS
ION
YUASA AND HARALAW, PATENT, TRADEMARK & DESIGN and ACCOUNTING
YUASA AND HARALAW, PATENT, TRADEMARK & DESIGN and ACCOUNTING
12
JPO’s Interpretation of Statutory Law
• In judging requirements for registration for extension, JPO considers “the scope of a patent right to be extended.”
• JPO’s Interpretation:• “product” “an active ingredient”• “use” “efficacy / effect”
• [An extended] patent right shall not be effective against any act other than the working of the patented invention for “the product” which was the subject of the approval […] (where the specific use of the product is prescribed by the disposition, the product used for that “use”). Section 68-2.
LAW
DIVIS
ION
PATENT
DIVIS
ION
TRADEMARK
& DESIG
N
DIVIS
ION
ACCOUNTING
& AUDIT
ING
DIVIS
ION
YUASA AND HARALAW, PATENT, TRADEMARK & DESIGN and ACCOUNTING
YUASA AND HARALAW, PATENT, TRADEMARK & DESIGN and ACCOUNTING
13
JPO’s Practice and Court’s Precedents
• JPO’s Practice:• [W]hen approvals are granted to pharmaceuticals
with the same active ingredient (product) and the same efficacy / effect (use) and differing only in […] dosage forms, etc., patent term extension shall be granted on basis of the earliest approval only. Examination Guidelines Part IV 3-1-1(1)
• Court’s precedents upheld JPO’s practice.
LAW
DIVIS
ION
PATENT
DIVIS
ION
TRADEMARK
& DESIG
N
DIVIS
ION
ACCOUNTING
& AUDIT
ING
DIVIS
ION
YUASA AND HARALAW, PATENT, TRADEMARK & DESIGN and ACCOUNTING
YUASA AND HARALAW, PATENT, TRADEMARK & DESIGN and ACCOUNTING
14
Extension Inapplicable to Later Approval
Chemical substance patent
patent term expires
filingdate
extension periodfor medical use A
extension period for medical use B
extension period5 years maximum
later approval of dosage form of medical use B
time
patent term20 years
same active ingredientsame efficacy / effectdifferent dosage form
Extension is inapplicable to a later approval for dosage form if there is a preceding approval in which active ingredient and efficacy / effect are the same
LAW
DIVIS
ION
PATENT
DIVIS
ION
TRADEMARK
& DESIG
N
DIVIS
ION
ACCOUNTING
& AUDIT
ING
DIVIS
ION
YUASA AND HARALAW, PATENT, TRADEMARK & DESIGN and ACCOUNTING
YUASA AND HARALAW, PATENT, TRADEMARK & DESIGN and ACCOUNTING
15
IP High Court Cases
• Three cases are brought before IP High Court, challenging appropriateness of JPO’s interpretation of law and Court’s precedents.
IP High Court (Tokyo High Court)
No. 2008-10458, -10459, -10460
(May 29, 2009)
(decided on the same day by Judge Iimura’s panel)
These cases are related to different patents.
LAW
DIVIS
ION
PATENT
DIVIS
ION
TRADEMARK
& DESIG
N
DIVIS
ION
ACCOUNTING
& AUDIT
ING
DIVIS
ION
YUASA AND HARALAW, PATENT, TRADEMARK & DESIGN and ACCOUNTING
YUASA AND HARALAW, PATENT, TRADEMARK & DESIGN and ACCOUNTING
16
Preceding Approvalactive ingredient Aefficacy / effect Bdosage form C
Later Approvalactive ingredient Aefficacy / effect Bdosage form D
Patent Term Extension
• Takeda obtained two marketing approvals under the Pharmaceutical Affairs Law.
Facts in common among 3 cases
Takeda files an application forpatent term extension.
JPO examiner rejects the application due to an existence of the preceding approval .
LAW
DIVIS
ION
PATENT
DIVIS
ION
TRADEMARK
& DESIG
N
DIVIS
ION
ACCOUNTING
& AUDIT
ING
DIVIS
ION
YUASA AND HARALAW, PATENT, TRADEMARK & DESIGN and ACCOUNTING
YUASA AND HARALAW, PATENT, TRADEMARK & DESIGN and ACCOUNTING
17
Case Preceding Approval Later Approval
2008-10458 Liquid / 5mg, 10mg Capsule / 30mg
2008-10459Injection solution
One-month sustained releaseInjection solution
Three-month sustained release
2008-10460 Liquid / 5mg, 10mg Capsule / 30mg
Facts – Details of Approvals
• Between preceding and later approvals,• Same active ingredient• Same efficacy / effect• Different dosage form
LAW
DIVIS
ION
PATENT
DIVIS
ION
TRADEMARK
& DESIG
N
DIVIS
ION
ACCOUNTING
& AUDIT
ING
DIVIS
ION
YUASA AND HARALAW, PATENT, TRADEMARK & DESIGN and ACCOUNTING
YUASA AND HARALAW, PATENT, TRADEMARK & DESIGN and ACCOUNTING
18
• Should “the scope of a patent right to be extended” be considered in judging requirements for registration for extension ?
Issues of the Cases
• Should “the product” in Section 68-2 (defining the scope of a patent right to be extended) be interpreted as “an active ingredient” ?
LAW
DIVIS
ION
PATENT
DIVIS
ION
TRADEMARK
& DESIG
N
DIVIS
ION
ACCOUNTING
& AUDIT
ING
DIVIS
ION
YUASA AND HARALAW, PATENT, TRADEMARK & DESIGN and ACCOUNTING
YUASA AND HARALAW, PATENT, TRADEMARK & DESIGN and ACCOUNTING
19
• Should “the scope of a patent right to be extended” be considered in judging requirements for registration for extension ?
Holding of the Cases
NO.
• Should “the product” in Section 68-2 (defining the scope of a patent right to be extended) be interpreted as “an active ingredient” ? NO.
LAW
DIVIS
ION
PATENT
DIVIS
ION
TRADEMARK
& DESIG
N
DIVIS
ION
ACCOUNTING
& AUDIT
ING
DIVIS
ION
YUASA AND HARALAW, PATENT, TRADEMARK & DESIGN and ACCOUNTING
YUASA AND HARALAW, PATENT, TRADEMARK & DESIGN and ACCOUNTING
20
Holding of the Cases (cont’d)
• “product” means a product specified by “ingredient,” “amount,” and “structure” of the drug which is the subject of the disposition.
• “use” refers to a case of a use invention.
• To refuse an application for patent term extension, an examiner shall prove:• (i) that “the disposition designated by Cabinet Order”
does not dissolve prohibition of working of the patented invention; or
• (ii) that acts whose prohibition is dissolved by “the disposition designated by Cabinet Order” do not fall within acts of working of the patented invention.
LAW
DIVIS
ION
PATENT
DIVIS
ION
TRADEMARK
& DESIG
N
DIVIS
ION
ACCOUNTING
& AUDIT
ING
DIVIS
ION
YUASA AND HARALAW, PATENT, TRADEMARK & DESIGN and ACCOUNTING
YUASA AND HARALAW, PATENT, TRADEMARK & DESIGN and ACCOUNTING
21
• Patent term extension may be applicable to a later approval of dosage form.
• Pharmaceutical company can recoup more investment.
Effect of the Cases
Chemical substance patent
patent term expires
extension periodfor medical use A
extension period for medical use B
extension period5 years maximum
patent term20 years
later approval of dosage form of medical use B
LAW
DIVIS
ION
PATENT
DIVIS
ION
TRADEMARK
& DESIG
N
DIVIS
ION
ACCOUNTING
& AUDIT
ING
DIVIS
ION
YUASA AND HARALAW, PATENT, TRADEMARK & DESIGN and ACCOUNTING
YUASA AND HARALAW, PATENT, TRADEMARK & DESIGN and ACCOUNTING
22
• IP High Court denies JPO’s interpretation of the statutory law.
• IP High Court vacates its own precedents.• Possible effects on Patent Law Reform
• Ministry of Economy, Trade and Industry (METI) has studied on possibility of reforming patent term extension system, but now stops proceeding of the study until the decisions of these three cases become conclusive and final.
Short Summary
LAW
DIVIS
ION
PATENT
DIVIS
ION
TRADEMARK
& DESIG
N
DIVIS
ION
ACCOUNTING
& AUDIT
ING
DIVIS
ION
YUASA AND HARALAW, PATENT, TRADEMARK & DESIGN and ACCOUNTING
YUASA AND HARALAW, PATENT, TRADEMARK & DESIGN and ACCOUNTING
23
What comes the next ?
• JPO appeals to the Supreme Court• Need to pay attention to the progress before the S. Ct.
• Whether a writ of cert is granted• If granted, how the S. Ct. decides the cases
Trick or Treat !
Supreme Court
OR
LAW
DIVIS
ION
PATENT
DIVIS
ION
TRADEMARK
& DESIG
N
DIVIS
ION
ACCOUNTING
& AUDIT
ING
DIVIS
ION
YUASA AND HARALAW, PATENT, TRADEMARK & DESIGN and ACCOUNTING
YUASA AND HARALAW, PATENT, TRADEMARK & DESIGN and ACCOUNTING
24
LAW
DIVIS
ION
PATENT
DIVIS
ION
TRADEMARK
& DESIG
N
DIVIS
ION
ACCOUNTING
& AUDIT
ING
DIVIS
ION
YUASA AND HARALAW, PATENT, TRADEMARK & DESIGN and ACCOUNTING
LAW
DIVIS
ION
PATENT
DIVIS
ION
TRADEMARK
& DESIG
N
DIVIS
ION
ACCOUNTING
& AUDIT
ING
DIVIS
ION
YUASA AND HARALAW, PATENT, TRADEMARK & DESIGN and ACCOUNTING
Thank you for your attention !
Koji Hirayama YUASA and HARA